Wednesday, August 7, 2019

Recent Trends in Oncology


EMA recommend approval of pembrolizumab and axitinib combination for first line treatment of advanced renal cell carcinoma. Explore more about oncology at: http://bit.ly/2K4sRl4
#CancerConference #OncologyConferences

No comments:

Post a Comment